vs
Side-by-side financial comparison of EPAM Systems (EPAM) and Hologic (HOLX). Click either name above to swap in a different company.
EPAM Systems is the larger business by last-quarter revenue ($1.4B vs $1.0B, roughly 1.3× Hologic). Hologic runs the higher net margin — 17.1% vs 7.8%, a 9.3% gap on every dollar of revenue. On growth, EPAM Systems posted the faster year-over-year revenue change (12.8% vs 2.5%). EPAM Systems produced more free cash flow last quarter ($268.1M vs $215.2M). Over the past eight quarters, EPAM Systems's revenue compounded faster (9.9% CAGR vs 1.5%).
EPAM Systems, Inc. is an American company that specializes in software engineering services, digital platform engineering, and digital product design, operating out of Newtown, Pennsylvania. EPAM is a founding member of the MACH Alliance.
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
EPAM vs HOLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $1.0B |
| Net Profit | $109.4M | $179.1M |
| Gross Margin | 30.1% | 56.0% |
| Operating Margin | 10.6% | 22.6% |
| Net Margin | 7.8% | 17.1% |
| Revenue YoY | 12.8% | 2.5% |
| Net Profit YoY | 5.9% | -10.9% |
| EPS (diluted) | $1.97 | $0.79 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $1.0B | ||
| Q3 25 | $1.4B | $1.0B | ||
| Q2 25 | $1.4B | $1.0B | ||
| Q1 25 | $1.3B | $1.0B | ||
| Q4 24 | $1.2B | $1.0B | ||
| Q3 24 | $1.2B | $988.0M | ||
| Q2 24 | $1.1B | $1.0B | ||
| Q1 24 | $1.2B | $1.0B |
| Q4 25 | $109.4M | $179.1M | ||
| Q3 25 | $106.8M | $187.2M | ||
| Q2 25 | $88.0M | $194.9M | ||
| Q1 25 | $73.5M | $-17.4M | ||
| Q4 24 | $103.3M | $201.0M | ||
| Q3 24 | $136.3M | $178.6M | ||
| Q2 24 | $98.6M | $194.5M | ||
| Q1 24 | $116.2M | $169.9M |
| Q4 25 | 30.1% | 56.0% | ||
| Q3 25 | 29.5% | 55.6% | ||
| Q2 25 | 28.8% | 56.3% | ||
| Q1 25 | 26.9% | 37.5% | ||
| Q4 24 | 30.4% | 56.8% | ||
| Q3 24 | 34.6% | 56.4% | ||
| Q2 24 | 29.3% | 55.4% | ||
| Q1 24 | 28.4% | 53.3% |
| Q4 25 | 10.6% | 22.6% | ||
| Q3 25 | 10.4% | 22.6% | ||
| Q2 25 | 9.3% | 24.9% | ||
| Q1 25 | 7.6% | -0.7% | ||
| Q4 24 | 10.9% | 22.5% | ||
| Q3 24 | 15.2% | 23.3% | ||
| Q2 24 | 10.5% | 24.1% | ||
| Q1 24 | 9.5% | 20.7% |
| Q4 25 | 7.8% | 17.1% | ||
| Q3 25 | 7.7% | 17.8% | ||
| Q2 25 | 6.5% | 19.0% | ||
| Q1 25 | 5.6% | -1.7% | ||
| Q4 24 | 8.3% | 19.7% | ||
| Q3 24 | 11.7% | 18.1% | ||
| Q2 24 | 8.6% | 19.2% | ||
| Q1 24 | 10.0% | 16.7% |
| Q4 25 | $1.97 | $0.79 | ||
| Q3 25 | $1.91 | $0.84 | ||
| Q2 25 | $1.56 | $0.86 | ||
| Q1 25 | $1.28 | $-0.08 | ||
| Q4 24 | $1.80 | $0.87 | ||
| Q3 24 | $2.37 | $0.75 | ||
| Q2 24 | $1.70 | $0.82 | ||
| Q1 24 | $1.97 | $0.72 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $2.4B |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $3.7B | $5.2B |
| Total Assets | $4.9B | $9.2B |
| Debt / EquityLower = less leverage | — | 0.48× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.2B | $2.2B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.2B | $1.6B | ||
| Q4 24 | $1.3B | $2.0B | ||
| Q3 24 | $2.1B | $2.3B | ||
| Q2 24 | $1.8B | $2.4B | ||
| Q1 24 | $2.0B | $2.2B |
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.5B | ||
| Q3 24 | — | $2.5B | ||
| Q2 24 | — | $2.5B | ||
| Q1 24 | — | $2.6B |
| Q4 25 | $3.7B | $5.2B | ||
| Q3 25 | $3.7B | $5.0B | ||
| Q2 25 | $3.7B | $4.8B | ||
| Q1 25 | $3.6B | $4.6B | ||
| Q4 24 | $3.6B | $4.8B | ||
| Q3 24 | $3.6B | $5.1B | ||
| Q2 24 | $3.4B | $5.0B | ||
| Q1 24 | $3.5B | $4.8B |
| Q4 25 | $4.9B | $9.2B | ||
| Q3 25 | $4.8B | $9.0B | ||
| Q2 25 | $4.7B | $8.8B | ||
| Q1 25 | $4.7B | $8.5B | ||
| Q4 24 | $4.8B | $8.7B | ||
| Q3 24 | $4.5B | $9.2B | ||
| Q2 24 | $4.2B | $8.9B | ||
| Q1 24 | $4.4B | $8.7B |
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.50× | ||
| Q2 25 | — | 0.52× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | — | 0.53× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | — | 0.53× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $282.9M | $229.9M |
| Free Cash FlowOCF − Capex | $268.1M | $215.2M |
| FCF MarginFCF / Revenue | 19.0% | 20.5% |
| Capex IntensityCapex / Revenue | 1.1% | 1.4% |
| Cash ConversionOCF / Net Profit | 2.59× | 1.28× |
| TTM Free Cash FlowTrailing 4 quarters | $612.7M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.9M | $229.9M | ||
| Q3 25 | $294.7M | $355.1M | ||
| Q2 25 | $53.2M | $343.3M | ||
| Q1 25 | $24.2M | $169.4M | ||
| Q4 24 | $130.3M | $189.3M | ||
| Q3 24 | $242.0M | $367.0M | ||
| Q2 24 | $57.0M | $405.8M | ||
| Q1 24 | $129.9M | $292.4M |
| Q4 25 | $268.1M | $215.2M | ||
| Q3 25 | $286.4M | $341.4M | ||
| Q2 25 | $43.4M | $330.5M | ||
| Q1 25 | $14.8M | $153.9M | ||
| Q4 24 | $114.5M | $172.5M | ||
| Q3 24 | $237.0M | $350.6M | ||
| Q2 24 | $52.3M | $385.3M | ||
| Q1 24 | $123.2M | $279.6M |
| Q4 25 | 19.0% | 20.5% | ||
| Q3 25 | 20.5% | 32.5% | ||
| Q2 25 | 3.2% | 32.3% | ||
| Q1 25 | 1.1% | 15.3% | ||
| Q4 24 | 9.2% | 16.9% | ||
| Q3 24 | 20.3% | 35.5% | ||
| Q2 24 | 4.6% | 38.1% | ||
| Q1 24 | 10.6% | 27.5% |
| Q4 25 | 1.1% | 1.4% | ||
| Q3 25 | 0.6% | 1.3% | ||
| Q2 25 | 0.7% | 1.3% | ||
| Q1 25 | 0.7% | 1.5% | ||
| Q4 24 | 1.3% | 1.6% | ||
| Q3 24 | 0.4% | 1.7% | ||
| Q2 24 | 0.4% | 2.0% | ||
| Q1 24 | 0.6% | 1.3% |
| Q4 25 | 2.59× | 1.28× | ||
| Q3 25 | 2.76× | 1.90× | ||
| Q2 25 | 0.60× | 1.76× | ||
| Q1 25 | 0.33× | — | ||
| Q4 24 | 1.26× | 0.94× | ||
| Q3 24 | 1.77× | 2.05× | ||
| Q2 24 | 0.58× | 2.09× | ||
| Q1 24 | 1.12× | 1.72× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPAM
Segment breakdown not available.
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
